Depresión, ansiedad y fibromialgia / Depression, anxiety and fibromyalgia

Objetivo. El objetivo del presente artículo es reflejar la asociación existente entre la fibromialgia y los trastornos psicológicos y psiquiátricos. La fibromialgia es una enfermedad que cursa con dolor crónico, de difícil tratamiento, que está estrechamente relacionada con trastornos psicológicos y psiquiátricos, siendo los más frecuentes la ansiedad y la depresión. Los mecanismos fisiopatogénicos de dicha asociación no son bien conocidos, pero se han realizado numerosos estudios en los que se intenta explicar dicha asociación. Material, métodos y resultados. Se realiza una revisión bibliográfica de los estudios realizados que intentan explicar dicha asociación, así como una revisión de los mecanismos etiopatogénicos comunes a dichas patologías. Conclusiones. La fibromialgia es una patología que cursa con dolor crónico y que está asociada a patología psiquiátrica. Dicha asociación puede ser causal, comorbilidad o secundaria a dicho proceso. Asimismo, influye negativamente en el proceso retrasando la mejoría del paciente (AU)

Objective. The aim of the present article is to examine the existing relationship between fibromyalgia and psychological and psychiatric disorders. Fibromyalgia is a disease that involves difficult to treat chronic pain that is closely related to psychological and psychiatric disorders, of which anxiety and depression are the most common. The pathophysiological mechanisms of this relationship are not well known, but a number of studies have been conducted in an attempt to explain this relationship. Material, methods and results. A literature review has been made on all the studies carried out that attempt to explain this relationship, as well as a review of the aetio-pathogenic mechanisms common to these pathologies. Conclusions. Fibromyalgia is a disease that involves chronic pain and is associated with psychiatric illness. This association may be causal, a comorbidity or secondary to this condition. It also has a negative influence on the disease, delaying the improvement of the patient (AU)

[Multicenter comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis]. / Estudio comparativo multicéntrico de la calcitonina sintética de salmón, administrada por vía nasal en el tratamiento de la osteoporosis postmenopáusica establecida.

We study the effectivity and tolerance of synthetic salmon calcitonin nasally administered (Miacalcic) in the treatment of established postmenopausic osteoporosis. During one year, two randomized groups of postmenopausic women diagnosed of osteoporosis were treated in an outpatient service either with 1 gr of calcium element per day during the whole study or with 100 daily I.U. of salmon synthetic calcitonin nasally administered in patterns of 14 days and the same period of rest, plus a supplement of 500 mgr of calcium element per day. Globally, 43 patients were assessed at the end of the study in the calcitonin plus calcium group and 45 in the group receiving only calcium. The main evaluation parameters were pain and presence of new fractures. At the beginning and at the end of the study, complementary tests of blood biochemistry were conducted, including alkalin phosphatase, calcium, phosphorus and uric acid, as well as calcium, hydroxiprolin and creatinini in the urine. The results showed a significant improvement of pain (p < 0.001) in the group treated with calcitonin, supported by a lower consumption of analgesics. The rate of vertebral fractures determined according to the Meunier's index, was also significantly lower (p < 0.001) in the group treated with calcitonin at the end of the study period. These results suggest that, compared to only calcium, nasally administered calcitonin precludes the formation of new vertebral fractures during one year of treatment and it is effective in terms of pain reduction.(ABSTRACT TRUNCATED AT 250 WORDS)